10 In a rapamycin-resistant diffuse large B-cell lymphoma model, a gene expression profile was generated.27 This model identified lymphoma subsets that were resistant to mTOR inhibitor therapy and mapped compounds targeting Akt as a way of reversing mTOR inhibitor resistance.27 MK-2206 and a rapalog combination was synergistic in other types of malignancies such as B-precursor acute lymphoblastic leukemia,28 cholangiocarcinoma,29 hepatocellular carcinoma30, 31 and neuroblastoma32in vitro and in vivo, in multiple myeloma,33 gastric cancer34 and thyroid cancer35in vitro. This evidence concerns the gene MTOR and plasma cell myeloma.